Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.

ABSTRACT:

Objective

Little is known about genetic contributors to higher than usual warfarin dose requirements, particularly for African Americans. This study tested the hypothesis that the γ-glutamyl carboxylase (GGCX) genotype contributes to warfarin dose requirements greater than 7.5 mg/day in an African American population.

Methods

A total of 338 African Americans on a stable dose of warfarin were enrolled. The GGCX rs10654848 (CAA)n, rs12714145 (G>A), and rs699664 (p.R325Q); VKORC1 c.-1639G>A and rs61162043; and CYP2C9*2, *3, *5, *8, *11, and rs7089580 genotypes were tested for their association with dose requirements greater than 7.5 mg/day alone and in the context of other variables known to influence dose variability.

Results

The GGCX rs10654848 (CAA)16 or 17 repeat occ

SUBMITTER: Cavallari LH 

PROVIDER: S-EPMC3261355 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature